THE PREVALENCE AND IMPACT OF HEPATIC STEATOSIS ON RESPONSE TO DAA THERAPY IN HIV-HCV COINFECTION.

被引：0
|
作者：
Johnson, Leigh P. [1 ]
Sterling, Richard K. [2 ]
机构：
[1] Virginia Commonwealth Univ, Internal Med, Richmond, VA 23284 USA
[2] Virginia Commonwealth Univ, Dept Internal Med, Div Gastroenterol Hepatol & Nutr, Richmond, VA 23284 USA
来源：
HEPATOLOGY | 2019年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1601
引用
收藏
页码：964A / 965A
页数：2
相关论文
共 50 条
  • [21] Impact of SVR to IFN-free DAA therapy on steatosis in HIV/HCV coinfected patients
    Chromy, D.
    Schwabl, P.
    Bucsics, T.
    Scheiner, B.
    Schmidbauer, C.
    Aichelburg, M.
    Ferenci, P.
    Trauner, M.
    Reiberger, T.
    Mandorfer, M.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S548 - S548
  • [22] The impact of HIV therapy with HAART on HCV disease in HIV/HCV coinfection
    Roychowdhury, A
    Lambiase, LR
    Monteiro, C
    Cubbedge, L
    Allen, J
    Li, JJ
    GASTROENTEROLOGY, 2001, 120 (05) : A369 - A369
  • [23] Hepatic steatosis in patients with HIV-HCV coinfection enrolled in the aids PEGASYS ribavirin international co-infection trial (APRICOT): Clinical characteristics and response to treatment
    Rodriguez-Torres, M
    Clumeck, N
    Lissen, E
    Sette, H
    Buggisch, P
    DePamphilis, J
    Dieterich, D
    HEPATOLOGY, 2005, 42 (04) : 667A - 667A
  • [24] Mechanisms of Accelerated Liver Fibrosis in HIV-HCV Coinfection
    Chrysanthidis, Theofilos
    Loli, Georgia
    Metallidis, Simeon
    Germanidis, Georgios
    AIDS REVIEWS, 2017, 19 (03) : 148 - 155
  • [25] Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfection
    Neukam, Karin
    Munteanu, Daniela
    Haubitz, Sebastian
    Mira, Jose A.
    Ingiliz, Patrick
    Rivero-Juarez, Antonio
    Lutz, Thomas
    de los Santos-Gil, Ignacio
    Scholten, Stefan
    Marquez, Manuel
    Rauch, Andri
    Rockstroh, Juergen K.
    Pineda, Juan A.
    ANTIVIRAL THERAPY, 2015, 20 (04) : 407 - 413
  • [26] A Prospective Study of The Association of Body Morphometry With Hepatic Steatosis and Fibrosis in HIV-HCV Coinfected Patients
    Awad, Chadi M.
    Nguyen, Tuyet A.
    Puri, Puneet
    Sanyal, Arun J.
    Luketic, Velimir A.
    Stravitz, R. Todd
    Siddique, Mohammad S.
    Bouneva, Iliana
    Sterling, Richard K.
    HEPATOLOGY, 2013, 58 : 1305A - 1306A
  • [27] Increased plasma lipoperoxidation and protein oxidation in HIV-HCV coinfection
    Sob, JE
    Ngondi, JL
    Oben, J
    FREE RADICAL BIOLOGY AND MEDICINE, 2005, 39 : S130 - S130
  • [28] Effectiveness of direct-acting antiviral therapy in patients with a HCV/HIV coinfection. A multicenter cohort study
    Rial-Crestelo, David
    Rodriguez-Cola, Miguel
    Javier Gonzalez-Gasca, Francisco
    Geijo-Martinez, Paloma
    Belinchon-Moya, Olga
    Martinez-Alfaro, Elisa
    Mateos-Rodriguez, Fernando
    Ramon Barbera, Jose
    Yzusqui, Miguel
    Casallo, Sonia
    Garcia, Maria
    Espinosa-Gimeno, Alfredo
    Torralba, Miguel
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2018, 110 (01) : 35 - 42
  • [29] ANRS HC 02 RIBAVIC: Impact of steatosis in HIV-HCV co-infection
    Pol, S.
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2009, 33 : S110 - S112
  • [30] HIV protease inhibitors do not reduce hepatitis C virus (HCV) replication in patients with HIV and HCV coinfection.
    Erhardt, A
    Mauss, S
    Adams, O
    Jablonowski, H
    Niederau, C
    Haussinger, D
    HEPATOLOGY, 1997, 26 (04) : 737 - 737
12345